Q-omics provides the consensus-scored PTGS1 profile across patient tissues and cancer cell-line models. PTGS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PTGS1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, PTGS1 protein abundance shows 22,073 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where PTGS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTGS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTGS1 survival associations across molecular data types. PTGS1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTGS1 RNA expression–survival associations across cancer types. High PTGS1 expression shows unfavorable associations in UVM, LGG, LAML and BLCA, but favorable associations in MESO and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PTGS1 RNA expression.
This table summarizes PTGS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTGS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTGS1 shows lower tumor expression in BLCA, COAD, KICH, STAD, LUSC and LUAD. The BLCA box plot shows higher PTGS1 RNA expression in normal versus tumor tissue (log2 FC = −6.200, t-test p < 0.001).
This table shows molecular features associated with PTGS1 in patient tissues and cancer cell lines. In patient samples, PTGS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTGS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
